News

Ahead of World Obesity Day on 4 March, Yazen is sharing new findings from internal patient data, revealing that shame and stigma remain major barriers to obesity care — even as effective medical treatments become more widely available.

UK employers are increasingly considering weight-loss support as part of employee benefits, as new Yazen patient data links GLP-1 treatment to reduced sick days and improved workplace performance.

In 2025, Yazen's revenue surged 87% to nearly €29.4 million, with gross profits doubling to €16.5 million. Now treating over 37,000 active patients across seven countries, the company is eyeing further expansion into two more markets in 2026. Despite an EBITDA of –€5.7 million due to heavy growth investment, Yazen remains a leader in European obesity care.

Yazen presents an oral scientific abstract at the Nordic Obesity Meeting (NOM26), highlighting high-volume patient–caregiver interactions in a fully digital obesity care model.

Yazen’s work powering digital patient transformation for sustainable weight care is recognised by the HTN Now 2025/26 Awards in the category of Digital Patient Transformation.

Weight management patients show lasting alcohol reduction with health benefits extending beyond temporary Dry January abstinence, new research reveals.

Discover why weight loss medications must come from registered clinicians. Learn to identify illegitimate sellers and protect yourself from dangerous counterfeit GLP-1 treatments in the UK.

Yazen makes the festive period easier for people on weight loss injections with a Christmas buffet strategy to instill confidence not fear!

As the countdown to Christmas begins, for the estimated 1.5 million people in the UK using GLP-1/GIP weight loss medications, the fear of navigating the festive period without "falling off the wagon" is a number one concern. Digital healthcare provider Yazen is tackling this "festive food noise fear" with a practical survival guide and a new online series featuring world-class chef Tristan Welch and TV icon Gemma Collins.

The WHO released its first global guideline for GLP-1 obesity treatment, recognizing obesity as a chronic disease. Long-term care combined with therapy is key.

Reality star Gemma Collins opens up to The Mirror about her 3.5 stone weight loss journey with Yazen. Find out how she's keeping it off for good.

Yazen wins “Weight Loss Treatment of the Year 2025 award” for its innovative, evidence-based care helping over 47,000 patients achieve sustainable weight loss.

Gemma Collins joins forces with Michelin-star chef Tristan Welch in an inspiring new weight-loss cooking series filled with flavorful recipes, expert tips, and transformative challenges.

Yazen, Europe’s leading digital healthcare provider in obesity care, has been ranked as the second fastest-growing startup in Europe by the Sifted 250: Startup Europe Leaderboard 2025.

Yazen named the fastest-growing startup in the Nordics and Benelux in the Sifted 100 Leaderboard

At ECO 2025, Yazen presents data from 30,000+ patients, showing 16.6% weight loss after 18 months and 70% adherence to treatment with its digital care model.

Yazen partners with Withings to go beyond BMI for better health insights.

Gemma Collins reveals her two dress size drop, crediting Yazen’s weight loss programme for helping her achieve a healthier, happier lifestyle.

Gemma Collins reveals her weight loss journey with Yazen’s weight-loss programme, sharing how it has transformed her health and happiness.

Gemma Collins has unveiled her stunning weight loss, crediting Yazen’s GLP-1 programme and injections for helping her feel healthier, happier, and free from dieting struggles.